Open AccessABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study
Author(s) -
Paolo Strati,
Michelle A. Fanale,
Yasuhiro Oki,
Francesco Turturro,
Luis Fayad,
Nancy L. Bartlett,
Douglas E. Gladstone,
Yvette L. Kasamon,
Carol S. Portlock,
Wyndham H. Wilson,
André Goy,
Anas Younes,
Hun Ju Lee
Publication year - 2018
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2018.199844
Subject(s) - abvd , rituximab , medicine , dacarbazine , lymphoma , oncology , classical hodgkin lymphoma , hodgkin lymphoma , chemotherapy , vincristine , cyclophosphamide